論文・総説 - 田中　真二

181. Tanaka S, Sugimachi K, Maehara Si, Shimada M, Maehara Y. . Tanaka S, Sugimachi K, Maehara Si, Shimada M, Maehara Y. A loss of function mutation in WISP3 derived from microsatellite unstable gastric carcinoma. Gastroenterology, 125:1563-4, 2003 Gastroenterology, 125:1563-4, 2003. 2003;

182. Tanaka S, Sugimachi K, Yamashita Yi, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K. . Tanaka S, Sugimachi K, Yamashita Yi, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology, 35:861-7, 2002 Hepatology, 35:861-7, 2002. 2002;

183. Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. . Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. Variant WISPs as targets for gastrointestinal carcinomas. Gastroenterology, 123:392-3, 2002 Gastroenterology, 123:392-3, 2002. 2002;

184. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y, Sugimachi K. . Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y, Sugimachi K. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene, 20:5525-32, 2001 Oncogene, 20:5525-32, 2001. 2001;

185. Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. . Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. Journal of Hepatology, 35:74-79, 2001 Journal of Hepatology, 35:74-79, 2001. 2001;

186. Etoh T, Inoue H, Tanaka S, Bernard GF, Kitano S, Mori M. . Etoh T, Inoue H, Tanaka S, Bernard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases. Cancer Research, 61:2145-2153, 2001 Cancer Research, 61:2145-2153, 2001. 2001;

187. Yamashita Yi, Shimada M, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, Sugimachi K. . Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Research. 2001; 61 1005-1012.

188. Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR, Sugimachi K. . Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR, Sugimachi K. Expression and anti-tumor effects of TRAIL in human cholangiocarcinoma. Hepatology, 32:523-527, 2000 Hepatology, 32:523-527, 2000. 2000;

189. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. Journal of Clinical Investigation, 103(3): 341-5, 1999 1999;

190. Fujie T, Tanaka F, Tahara K, Li J, Tanaka S, Mori M, Ueo H, Takesako K, Akiyoshi T. Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide. Cancer Immunology and Immunotherapy, 48(4): 189-94, 1999 1999;

191. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. International Journal of Oncology, 15(4): 687-92, 1999 1999;

192. Shibata K, Tanaka S, Shiraishi T, Kitano S, Mori M. G-protein gamma 7 is down-regulated in cancers and associated with p 27kip1-induced growth arrest. Cancer Research, 59(5): 1096-101, 1999 Cancer Research, 59(5): 1096-101, 1999. 1999;

193. Watanabe M, Kuwano H, Tanaka S, Toh Y, Sadanaga N, Sugimachi K. Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus. Cancer, 85(11): 2322-8, 1999 1999;

194. Shimada M, Hasegawa H, Gion T, Shirabe K, Taguchi K, Takenaka K, Tanaka S, Sugimachi K. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology, 46(28): 2469-75, 1999 1999;

195. Watanabe M, Kuwano H, Tanaka S, Toh Y, Masuda H, Sugimachi K. A significant morphological transformation is recognized in human esophageal cancer cells with an amplification/overexpression of the Cyclin D1 gene. International Journal of Oncology, 15(6): 1103-1108, 1999 1999;

196. Mori M, Shiraishi T, Tanaka S, Yamagata M, Mafune K, Tanaka Y, Ueo H, Barnard GF, Sugimachi K. Lack of DMBT1 expression in oesophageal, gatric and colon cancer. British Journal of Cancer, 79(2): 211-213, 1999 1999;

197. de la Monte SM, Ganju N, Tanaka S, Banerjee K, Karl PJ, Brown NV, Wands JR.. Differential effects of ethanol on insulin-signaling through the insulin receptor substrate-1. Alcoholism, Clinical and Experimental Research. 1999; 23 (5): 770-777. ( PubMed, DOI )

198. Tanaka S, Komori K, Sugimachi K. Cytomegalovirus infection in aortic aneurysms. Journal of Vascular Surgery, 27(3): 587-588, 1998 1998;

199. Mohr L, Tanaka S, Wands JR. Ethanol inhibits hepatocytes proliferation through the IRS-1 signal transduciton pathway in transgene mice. Gastroenterology, 115(6): 1558-65, 1998 1998;

200. Shiraishi T, Mori M, Tanaka S, Sugimachi K, Akiyoshi T. Identification of cystatin B in human esophageal carcinoma using differential displays in which the gene expression is related to lymph node metastasis. International Journal of Cancer, 79(2): 175-178, 1998 1998;